Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 6/20 | 0.34 |
| ▸ | FABP3 | P05413 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20344844 | 1.00 | CLK1 (0.35) | CLK1NPC1RAB9AFABP4FABP3 | |
| SCHEMBL17029066 | 0.94 | P2RX3 (0.36) | FABP4FABP3NR1I2P2RX3 | |
| SCHEMBL17029065 | 0.94 | P2RX3 (0.36) | FABP4FABP3NR1I2P2RX3 | |
| SCHEMBL17039251 | 0.94 | P2RX3 (0.36) | FABP4FABP3NR1I2P2RX3 | |
| SCHEMBL17029018 | 0.92 | NR1I2 (0.40) | FABP4FABP3NR1I2 | |
| SCHEMBL18364988 | 0.83 | NR1I2 (0.36) | FABP4FABP3NR1I2P2RX3 | |
| SCHEMBL20344817 | 0.83 | NR1I2 (0.36) | FABP4FABP3NR1I2P2RX3 | |
| SCHEMBL17039255 | 0.83 | CLK1 (0.40) | CLK1NPC1RAB9AFABP4FABP3 | |
| SCHEMBL18364984 | 0.83 | NR1I2 (0.39) | FABP4FABP3NR1I2 | |
| SCHEMBL17039253 | 0.83 | NR1I2 (0.39) | FABP4FABP3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | CLK1 2640/4885NPC1 434/4885RAB9A 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.